Neuro-Oncology Journal

•  
• Overview
•  
• Identity
•  
• View All
•  

Overview

publication venue for

• HIGHER VINCRISTINE DOSES CORRELATE WITH LONGER OVERALL SURVIVAL: A POST-HOC ANALYSIS OF PARTICIPANTS RECEIVING PCV ON RTOG 9402 2023
• IMMUNOTHERAPEUTIC TARGETING OF FIBROBLAST ACTIVATION PROTEIN (FAP) IN TREATMENT REFRACTORY GLIOBLASTOMA USING NOVEL CAR-T CELL THERAPY 2023
• UPDATED RESULTS AND MOLECULAR SUBGROUP ANALYSES FROM THE RANDOMIZED PHASE 3 MIRAGE TRIAL ON MARIZOMIB IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA 2023
• Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539. 2023
• DEVELOPMENT OF NOVEL ANTI-BRAIN METASTASIS INHIBITORS 2022
• DISCOVERY OF DYNAMIC MINIMAL RESIDUAL DISEASE STATES IN ADULT GLIOBLASTOMA USING SINGLE CELL TECHNOLOGY 2022
• ITGA5 IS A NOVEL IMMUNOTHERAPEUTIC TARGET AGAINST TREATMENT REFRACTORY MEDULLOBLASTOMA 2022
• NON-GENOMIC DETERMINANTS OF TUMOR CELL PHENOTYPES IN ADULT GLIOBLASTOMA. 2022
• AN IN VIVO FUNCTIONAL GENOMICS SCREEN TO IDENTIFY NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS 2021
• ANTI-ROBO1 CAR T CELLS EFFECTIVELY TARGET MALIGNANT BRAIN CANCER 2021
• FUNCTIONAL MAPPING REVEALS WIDESPREAD REMODELLING AND UNRECOGNIZED PATHWAY DEPENDENCIES IN RECURRENT GLIOBLASTOMA 2021
• THERAPEUTIC INTERVENTION OF LUNG-, BREAST-, AND MELANOMA-BRAIN METASTASIS 2021
• EMBR-22. RATIONAL DEVELOPMENT OF SYNERGISTIC THERAPIES ALONGSIDE BMI1 INHIBITION FOR GROUP 3 MEDULLOBLASTOMA 2021
• EPCT-12. NATIONAL MULTICENTERED RETROSPECTIVE REVIEW OF DEMOGRAPHIC, TUMOUR AND INTRAOPERATIVE FEATURES ASSOCIATED WITH THE DEVELOPMENT OF CEREBELLAR MUTISM AFTER PEDIATRIC POSTERIOR FOSSA TUMOUR RESECTION 2021
• QOL-02. PERCEPTIONS OF LATE EFFECTS CARE NEEDS AMONG SURVIVORS OF PEDIATRIC BRAIN TUMOURS 2020
• QOL-46. LATE EFFECTS CARE FOR CHILDHOOD BRAIN TUMOUR SURVIVORS: A QUALITY IMPROVEMENT PROJECT 2020
• DISSECTING REGULATORS OF THE ABERRANT POST-TRANSCRIPTIONAL LANDSCAPE IN MYC-AMPLIFIED GROUP 3 MEDULLOBLASTOMA 2020
• PERCEPTIONS OF LATE EFFECTS CARE NEEDS AMONG SURVIVORS OF PEDIATRIC BRAIN TUMOURS 2020
• EFFECT OF STEREOTACTIC RADIOSURGERY COMPARED TO WHOLE-BRAIN RADIOTHERAPY FOR LIMITED BRAIN METASTASIS ON LONG TERM COGNITION AND QUALITY OF LIFE: A POOLED ANALYSIS OF RANDOMIZED CLINICAL TRIALS 2020
• IDEAL TREATMENT REGIMEN FOR PATIENTS WITH >= 1 BRAIN METASTASIS FROM PRIMARY NON-SMALL-CELL LUNG CANCER - A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS 2020
• IDENTIFICATION OF NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS THROUGH IN VIVO FUNCTIONAL GENOMICS 2020
• TARGETING BRAIN METASTASIS-INITIATING CELLS: A PREVENTATIVE APPROACH 2020
• FINAL RESULTS WITH CHEMORADIOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIAL TUMORS FROM NRG ONCOLOGY/RTOG 9402 2019
• LEVERAGING FUNCTIONAL GENETIC DEPENDENCIES IN TREATMENT-REFRACTORY GLIOBLASTOMA 2019
• MEDU-10. THERAPEUTIC TARGETING OF STEM CELL SELF-RENEWAL IN CHILDHOOD MEDULLOBLASTOMA: STRATEGIES FOR BLOCKING RECURRENCE 2019
• GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE 2019
• MUSAShi-1 IS A MASTER REGULATOR OF ABERRANT TRANSLATION IN GROUP 3 MEDULLOBLASTOMA 2019
• SMALL MOLECULE INHIBITOR TARGETING SELF-RENEWAL AS A THERAPEUTIC OPTION FOR RECURRENT MEDULLOBLASTOMA 2019
• A COMMON FETAL DEVELOPMENTAL ORIGIN FOR PFA EPENDYMOMA, PFB EPENDYMOMA, AND CEREBELLAR PILOCYTIC ASTROCYTOMAS? 2018
• DOES EXERCISE IMPROVE PROGRESSION FREE SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH GLIOBLASTOMA? A TRIAL IN PROGRESS 2018
• DYNAMIC PATTERNS OF GLIOBLASTOMA CLONAL EVOLUTION IN RESPONSE TO CHEMORADIOTHERAPY 2018
• MATCHING OF SINGLE CELL TRANSCRIPTOMICS FROM CEREBELLAR DEVELOPMENT IDENTIFIES PUTATIVE SUBGROUP SPECIFIC CELLS OF ORIGIN FOR MEDULLOBLASTOMA 2018
• USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE IN GLIOMA PATIENTS 2018
• INVESTIGATING THE ROLE OF THE RNA BINDING PROTEIN, MUSASHI 1 IN PEDIATRIC GROUP 3 MEDULLOBLASTOMA 2018
• SALVAGE THERAPY FOR CHILDHOOD MEDULLOBLASTOMA: A SINGLE CENTER EXPERIENCE 2018
• A CD133-Akt-Wnt SIGNALING AXIS PROVIDES FUNCTIONAL INSIGHT INTO THE ROLE OF CD133 IN GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS 2017
• A SINGLE CENTER RESTROSPECTIVE REVIEW OF RECURRENT OR TREATMENT REFRACTORY PEDIATRIC MEDULLOBLASTOMA 2017
• CE7 CANADIAN CLINICAL TRIALS GROUP / ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY. A PHASE III TRIAL OF STEREOTACTIC RADIOSURGERY COMPARED WITH WHOLE BRAIN RADIOTHERAPY (WBRT) FOR 5-15 BRAIN METASTASES 2017
• CHARACTERIZATION OF THE CELL SURFACE PROTEOME IN RECURRENT GLIOBLASTOMA INITIATING CELLS 2017
• CLONAL DYNAMICS OF HUMAN GLIOBLASTOMA IN RESPONSE TO CHEMORADIOTHERAPY 2017
• CONTEXT-SPECIFIC TUMOR SUPPRESSIVE FUNCTION OF THE CANONICAL WNT PATHWAY IN PEDIATRIC MEDULLOBLASTOMA HIGHLIGHTS A THERAPEUTIC STRATEGY FOR TREATMENT-REFRACTORY SUBGROUPS 2017
• GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE 2017
• GENOME-WIDE CRISPR SCREENS IN BRAIN TUMOR INITIATING CELLS (BTICS) IDENTIFY POTENT SENSITIZERS OF CONVENTIONAL CHEMORADIOTHERAPY 2017
• IDENTIFICATION OF NOVEL MARKERS OF TREATMENT-REFRACTORY RECURRENT GLIOBLASTOMA 2017
• N107C/CEC.3 (ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY/CANADIAN CANCER TRIALS GROUP): PHASE III TRIAL OF POST-OPERATIVE RADIOSURGERY COMPARED WITH WHOLE BRAIN RADIOTHERAPY FOR RESECTED METASTATIC BRAIN DISEASE: COGNITIVE FUNCTION OF LONG-TERM SURVIVORS 2017
• PATTERNS OF TTFIELDS-RELATED SEVERE SKIN TOXICITY IN GBM PATIENTS 2017
• PRECLINICAL VALIDATION OF NOVEL THERAPEUTICS TARGETING A BMIC POPULATION IN HUMAN BRAIN METASTASES 2017
• PRELIMINARY SCREENING OF A NOVEL EpCAM BISPECIFIC T-CELL ENGAGER (BiTE) ANTIBODY TO TARGET A BMIC POPULATION IN HUMAN BRAIN METASTASES 2017
• PRETREATMENT VOLUME OF MRI-DETERMINED WHITE MATTER INJURY (WMI) PREDICTS COGNITIVE DECLINE AFTER HIPPOCAMPAL AVOIDANT (HA) WBRT FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGY RTOG 0933 2017
• THERAPEUTIC TARGETING OF TUMORIGENIC EphA2+/EphA3+BRAIN TUMOR INITIATING CELLS WITH BISPECIFIC ANTIBODY IN HUMAN GLIOBLASTOMA 2017
• TIME TO FUNCTIONAL AND COGNITIVE DECLINE IN A PHASE 3 TRIAL OF TUMOR TREATING FIELDS WITH TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA 2017
• CONTEXT-SPECIFIC TUMOR SUPPRESSIVE FUNCTION OF THE CANONICAL WNT PATHWAY IN PEDIATRIC MEDULLOBLASTOMA HIGHLIGHTS A THERAPEUTIC STRATEGY FOR TREATMENT-REFRACTORY SUBGROUPS 2017
• GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE 2017
• INVESTIGATING THE ROLE OF THE RNA BINDING PROTEIN, MUSASHI, IN GROUP 3 MEDULLOBLASTOMA 2017
• ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA 2016
• ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA 2016
• CHARACTERIZATION OF A UNIQUE BMIC POPULATION IN HUMAN BRAIN METASTASES 2016
• CHARACTERIZATION OF A UNIQUE BMIC POPULATION IN HUMAN BRAIN METASTASES 2016
• DEVELOPMENT AND APPLICATION OF A NOVEL MODEL OF HUMAN LUNG-TO-BRAIN METASTASIS TO IDENTIFY GENETIC REGULATORS OF BRAIN METASTASIS INITIATING CELLS 2016
• Developing models of therapy resistance for the identification of treatment-refractory cell population(s) in human glioblastoma 2016
• THE EFFICACY OF CD133 BiTEs AND CAR-T CELLS IN PRECLINICAL MODEL OF RECURRENT GLIOBLASTOMA 2016
• A MODEL OF CARE FOR PEDIATRIC CNS TUMOR PATIENTS 2016
• ACTIVATED Wnt SIGNALING FOR THE THERAPEUTIC TARGETING OF TREATMENT-REFRACTORY MEDULLOBLASTOMA STEM CELLS 2016
• ATYPICAL TERATOID RHABDOID TUMORS IN THE FIRST YEAR OF LIFE: SHOULD WE TREAT? 2016
• DOES DIAGNOSTIC DELAY AFFECT MORBIDITY IN CHILDREN DIAGNOSED WITH BRAIN TUMOURS? 2016
• IS A SEPARATE AFTERCARE CLINIC FOR PEDIATRIC CNS TUMOR PATIENTS NECESSARY? 2016
• MRI AND SURGICAL PARAMETERS TO DETERMINE THE RISK OF A CEREBELLAR MUTISM 2016
• NEURAL NETWORK DISTURBANCES IN CHILDREN TREATED FOR BRAIN TUMOURS 2016
• REPAIRING THE BRAIN WITH PHYSICAL EXERCISE: AN EXERCISE TRIAL IN PEDIATRIC BRAIN TUMOR SURVIVORS. INSIGHTS FROM CORTICAL THICKNESS ANALYSIS AND DEFORMATION BASED MORPHOMETRY 2016
• ACTIVATED Wnt SIGNALING TARGETS Sox2+TREATMENT-REFRACTORY Shh-DEPENDENT MEDULLOBLASTOMA STEM CELLS 2015
• DISCOVERING THE TREATMENT REFRACTORY BTIC POPULATION IN GROUP 3 MEDULLOBLASTOMA 2015
• NC-10 * TRAINING THE BRAIN TO REPAIR ITSELF: AN EXERCISE TRIAL IN PEDIATRIC BRAIN TUMOR SURVIVORS 2014
• RM-06 * IN VITRO CLONAL EVOLUTION OF GLIOBLASTOMA (GBM) BRAIN TUMOUR INITIATING CELLS (BTIC) TO MODEL TUMOUR RECURRENCE 2014
• SC-33 * POLYCOMB GROUP PROTEIN Bmi1 CONTROLS NEURAL STEM AND PROGENITOR CELL MAINTENANCE AND GLIOBLASTOMA TUMOUR DEVELOPMENT 2014
• IN VITRO ANALYSIS OF CYTOTOXIC EFFECTS OF BRIVARACETAM AND LACOSAMIDE ON HUMAN GLIOBLASTOMA CELLS 2014
• GLIOMA SPECIFIC PEPTIDES: A PLATFORM FOR MOLECULAR IMAGING AND THERAPEUTIC TARGETING 2014
• SOX2 IDENTIFIES THE TREATMENT-REFRACTORY STEM CELL POPULATION IN GROUP 2 MEDULLOBLASTOMA 2014
• EPIDEMIOLOGY OF MALIGNANT PONTINE GLIOMAS (MPG) IN THE PAEDIATRIC POPULATION IN CANADA: A STUDY OF THE CANADIAN PAEDIATRIC BRAIN TUMOUR CONSORTIUM (CPBTC) 2014
• EXERCISE INCREASES HIPPOCAMPAL VOLUME IN CHILDREN TREATED WITH CRANIAL RADIATION 2014
• NEUROCOGNITIVE EVALUATION OF LONG TERM SURVIVOR'S WITH ATYPICAL TERATOID/RHABDOID TUMOR (ATRT): THE CANADIAN REGISTRY EXPERIENCE 2014
• PERSONALIZING THE TREATMENT OF PEDIATRIC MEDULLOBLASTOMA: POLO-LIKE KINASE 1 AS A MOLECULAR TARGET IN HIGH-RISK CHILDREN 2014
• PROGNOSTIC ADVANTAGE OF SURVEILLANCE NEUROIMAGING IN MANAGEMENT OF PEDIATRIC BRAIN TUMOURS 2014
• DISTINGUISHING RESPONDERS FROM NON-RESPONDERS TO BEVACIZUMAB USING CT PERFUSION 2013
• MEMORY PRESERVATION WITH CONFORMAL AVOIDANCE OF THE HIPPOCAMPUS DURING WHOLE- BRAIN RADIOTHERAPY (WBRT) FOR PATIENTS WITH BRAIN METASTASES: PRELIMINARY RESULTS OF RTOG 0933 2013
• WEEKLY VINBLASTINE IN CHEMOTHERAPY NAIVE CHILDREN AND ADOLESCENT WITH UNRESECTABLE OR PROGRESSIVE LOW GRADE GLIOMA: A CANADIAN COOPERATIVE STUDY 2013
• Bmi1 REGULATES GLI ACETYLATION THROUGH CULLIN3 IN MEDULLOBLASTOMA STEM CELLS 2013
• CLONAL EVOLUTION OF MEDULLOBLASTOMA BRAIN TUMOUR-INITIATING CELLS (BTICS) IN RESPONSE TO THERAPY: DISCOVERING THE REFRACTORY BTIC POPULATION 2013
• MYXOPAPILLARY SPINAL EPENDYMOMAS DISPLAY A HIF1-ALPHA DRIVEN 'WARBURG' PHENOTYPE 2013
• PERSONALIZING THE TREATMENT FOR MEDULLOBLASTOMA: POLO-LIKE KINASE 1 (PLK1) AS A MOLECULAR TARGET FOR THE SONIC HEDGEHOG (SHH) SUBTYPE 2013
• REGULATION OF MEDULLOBLASTOMA STEM CELL SELF-RENEWAL THROUGH THE DEVELOPMENTALLY CONSERVED FoxG1-Bmi1-p21 AXIS 2013
• PRIMARY MALIGNANT BRAIN TUMORS IN THE ELDERLY: RETROSPECTIVE ANALYSIS OF MANAGEMENT AND OUTCOME 2012
• Bmi1 AND FoxG1 REGULATE SELF-RENEWAL IN CD15+non-Shh/Wnt SUBTYPE MEDULLOBLASTOMA STEM CELLS THROUGH RECIPROCAL PROMOTER OCCUPANCY 2012
• Bmi1 REGULATION OF SONIC HEDGEHOG SIGNALING THROUGH THE E3 UBIQUITIN LIGASE CULLIN3 IN MEDULLOBLASTOMA STEM CELLS 2012
• CHILDREN SURVIVING BRAIN TUMORS HAVE HIGH RATES OF OBESITY INDEPENDENT OF PUBERTY 2012
• DEVELOPMENT OF IN VITRO AND IN VIVO CHEMO-AND RADIOTHERAPY MODELS FOR DETECTION OF TREATMENT-REFRACTORY MEDULLOBLASTOMA BRAIN TUMOR-INITIATING CELLS 2012
• FITNESS, PHYSICAL ACTIVITY AND BODY COMPOSITION FOLLOWING TREATMENT FOR A CNS TUMOUR 2012
• FRACTIONATED STEREOTACTIC RADIOSURGERY FOR RELAPSED PAEDIATRIC PRIMITIVE NEUROECTODERMAL TUMOURS: A SINGLE INSTITUTION EXPERIENCE 2012
• HIGH-GRADE PAPILLARY TUMOUR OF THE PINEAL REGION IN A YOUNG CHILD WITH LEPTOMENINGEAL DISEASE 2012
• INCIDENCE OF MEDULLOBLASTOMA IN CANADIAN CHILDREN 2012
• PARENTAL KNOWLEDGE AND HEALTH CARE SATISFACTION WITH NEUROFIBROMATOSIS TYPE 1 2012
• PEDIATRIC AND ADULT MEDULLOBLASTOMA: WHAT MAKES THE DIFFERENCE IN OUTCOME? 2012
• PEDIATRIC INTRACRANIAL GERMINOMA CASE SERIES: FOUR PATIENTS WITH ATYPICAL CLINICO-RADIOLOGICAL PRESENTATION 2012
• POLO-LIKE KINASE 1 (PLK1) INHIBITION KILLS GLIOBLASTOMA MULTIFORME BRAIN TUMOUR CELLS IN PART THROUGH LOSS OF SOX2 AND DELAYS TUMOUR PROGRESSION IN MICE 2012
• RECURRENT ANAPLASTIC EPENDYMOMA WITH EXTRACRANIAL METASTASES - TREATMENT WITH SURGERY, RADIATION AND ORAL CHEMOTHERAPY 2012
• STRATIFICATION ACCORDING TO HGG-IMMUNO RPA MODEL PREDICTS OUTCOME IN PATIENTS WITH RELAPSED MALIGNANT GLIOMA TREATED BY ADJUVANT POSTOPERATIVE DC VACCINATION 2012
• YB-1 BRIDGES NEURAL STEM CELLS AND BRAIN TUMOR-INITIATING CELLS VIA ITS ROLES IN DIFFERENTIATION AND CELL GROWTH 2012
• GENOME-WIDE METHYLATED DNA RECOVERY IDENTIFIES FREQUENT HYPERMETHYLATION OF NOVEL TUMOR SUPPRESSOR GENES IN THE EPENDYMOMA EPIMETHYLGENOME 2011
• ROLE OF YB-1 ON GLIAL TUMORS AND ITS PROMISE AS A MOLECULAR TARGET 2011
• TARGETING POLO-LIKE KINASE FOR THE TREATMENT OF BRAIN TUMORS AND ITS UNIQUE CAPACITY TO ELIMINATE CANCER STEM CELLS THROUGH Sox-2 INHIBITION 2011
• Y-BOX BINDING PROTEIN-1 (YB-1) INHIBITION TRIGGERS DIFFERENTIATION OF NORMAL AND CANCER STEM CELLS FROM THE BRAIN 2011
• EPENDYMOMAS OF THE FILUM TERMINALE: A SINGLE-INSTITUTION EXPERIENCE 2010
• A HUGE INTRACRANIAL CHORIOCARCINOMA IN A 10-YEAR-OLD BOY SUCCESSFULLY TREATED WITH MULTIDISCIPLINARY THERAPY INCLUDING ENDOVASCULAR EMBOLIZATION 2010
• CEREBELLAR HEMANGIOBLASTOMA ASSOCIATED WITH VISCERAL AND CUTANEOUS HEMANGIOMATOSIS IN AN INFANT 2010
• CLAUDIN-6 AND INI-1 IMMUNOHISTOCHEMICAL EXPRESSION IN ATYPICAL TERATOID RHABDOID TUMOURS OF THE CNS 2010
• IMMUNOTHERAPY INTEGRATED IN RADIOCHEMOTHERAPY AND MAINTENANCE TENIOZOLOMIDE: FINAL RESULTS OF THE HGG-2006 STUDY 2010
• LATE EPENDYMOMA RELAPSES: A CANADIAN PEDIATRIC MULTICENTRE STUDY 2010
• MANAGEMENT OF AN INTRACRANIAL MATURE TERATOMA RECURRING AS A GERMINOMA 2010
• MEDULLOBLASTOMA OVER THREE DECADES IN A SINGLE INSTITUTION - WHAT HAVE WE ACHIEVED 2010
• REDEFINING THE INCIDENCE, OUTCOMES, AND PROGNOSTIC FACTORS FOR CNS ATYPICAL TERATOID RHABDOID TUMOURS AT BC CHILDREN'S HOSPITAL 2010
• REGULATION OF BMI1 BY THE SHH PATHWAY IN HUMAN MEDULLOBLASTOMA BRAIN TUMOUR INITIATING CELLS 2010
• A NEW IN VITRO ASSAY USING GAMMA KNIFE RADIOSURGERY ON CELLS FROM PRIMARY AND RECURRENT GBMS TO DETECT THE DEVELOPMENT OF RADIATION RESISTANCE IN RECURRENT TUMORS 2009
• INTEGRATION OF DC VACCINATION IN THE PRIMARY TREATMENT OF ADULTS WITH GLIOBLASTOMA: FINAL RESULTS OF THE HGG-2006 PHASE I/II TRIAL 2009
• PHASE II TRIAL OF CONVENTIONAL RADIOTHERAPY WITH STEREOTACTIC RADIOSURGERY TO HIGH-RISK TUMOR REGIONS AS DETERMINED BY MR SPECTROSCOPY IN PATIENTS WITH GLIOBLASTOMA MULTIFORME 2009
• PILOMYXOID ASTROCYTOMA IN TWO DIFFERENT AGE GROUPS 2009
• VALIDATION OF RPA CLASSIFICATION AS A PROGNOSTIC TOOL IN ADULT PATIENTS WITH RELAPSED HIGH-GRADE GLIOMA VACCINATED AT TIME OF RECURRENCE 2009
• A RETROSPECTIVE REVIEW OF THE INCIDENCE OF BRAIN METASTASES IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER 2008
• INTEGRATION OF DC VACCINATION IN THE PRIMARY TREATMENT OF ADULTS WITH GBM: UPDATE OF THE HGG-2006 PHASE I/II TRIAL 2008
• CNS atypical teratoid rhabdoid tumor (ATRT) in children less than 36 months: A Canadian pediatric brain tumor consortium (CPBTC) experience 2008
• Characterisation of the 4q12 amplicon in pediatric gliomas 2008
• Inducible Cre recombinase activity in mouse mature astrocytes and adult neural precursor cells: Developing novel animal models for glioma 2008
• More than words: Communication when a dying child can no longer speak 2008
• Phase 1 and pharmacokinetic studies of erlotinib administered concurrently with and after radiotherapy for children, adolescents, and young adults with high-grade glioma 2008
• Spinal cord tumors in infancy: A Canadian pediatric brain tumor consortium report 2008
• Cilengitide and synergy with radiation 2007
• Identification of known and novel recurrent amplified oncogenes in pediatric medulloblastoma 2007
• Multiple recurrent genetic events converge on proper control of histone 3 lysine 9 methylation in pediatric medulloblastoma 2007
• White matter integrity and core cognitive functions in children treated with cranial-spinal radiation: A diffusion tensor study 2007
• Imaging findings related to adjuvant dendritic cell (DC) vaccination in patients with relapsed high-grade glioma 2006
• Motexafin gadolinium (MGd) combined with whole-brain irradiation therapy prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Pooled analysis of two randomized phase 3 trials 2006
• Prodige: A phase 3 randomized placebo-controlled trial of thromboprophylaxis using dalteparin low-molecular-weight heparin (LMWH) in patients with newly diagnosed malignant glioma 2005
• High-resolution longitudinal screening with magnetic resonance imaging in a murine brain cancer model 2004
• Intensive therapy for childhood atypical teratoid rhabdold tumor of the central nervous system: A single institution's experience with four cases and a review of the literature 2004
• Disease stage-specific role of the mitochondrial pyruvate carrier suppresses differentiation in temozolomide and radiation-treated glioblastoma..  noaf008. 2025
• ENHANCING GLIOBLASTOMA TREATMENT: ALLOGENEIC CAR-T CELLS OVERCOMES FUNCTIONAL DEFICITS OF PATIENT-DERIVED AUTOLOGOUS PRODUCTS.  26. 2024
• LEVERAGING GENOME-WIDE CRISPR/CAS9 KNOCKOUT DRUG SCREENS TO IDENTIFY SENSITIZERS FOR PROTEOSOME INHIBITORS IN GLIOBLASTOMA.  26. 2024
• MULTI-OMIC CHARACTERIZATION OF THE TEMPORAL METABOLIC ADAPTATIONS UNDERPINNING THERAPY RESISTANCE AND TUMOR RECURRENCE IN GLIOBLASTOMA.  26. 2024
• PYROPTOSIS IS AN ACQUIRED VULNERABILITY OF BRAIN METASTASES.  26. 2024
• TARGETING AXONAL GUIDANCE DEPENDENCIES IN GLIOBLASTOMA WITH ROBO1 CAR T CELLS.  26. 2024
• THE UROKINASE RECEPTOR AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN BRAIN CANCERS.  26. 2024
• THERAPEUTIC TARGETING OF MISLOCALIZED NUCLEAR ENVELOPE PROTEINS INMYC-DRIVEN GROUP 3 MEDULLOBLASTOMA.  26. 2024
• A kinome drug screen identifies multi-TKI synergies and ERBB2 signaling as a therapeutic vulnerability in MYC/TYR subgroup atypical teratoid rhabdoid tumors.  26:1895-1911. 2024
• Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial..  26:1670-1682. 2024
• QOL-23. POTENTIAL MYELIN REPAIR AFTER IRRADIATED PEDIATRIC BRAIN TUMOR: A MAGNETIZATION TRANSFER IMAGING ANALYSIS.  26:0-0. 2024
• EXTH-08. IMMUNOTHERAPEUTIC TARGETING OF FIBROBLAST ACTIVATION PROTEIN (FAP) IN TREATMENT REFRACTORY GLIOBLASTOMA USING NOVEL CAR-T CELL THERAPY.  25:v225-v225. 2023
• QOL-18. HIGHER VINCRISTINE DOSES CORRELATE WITH LONGER OVERALL SURVIVAL: A POST-HOC ANALYSIS OF PARTICIPANTS RECEIVING PCV ON RTOG 9402.  25:v252-v252. 2023
• P02.16.B COMPENSATORY CROSS-TALK BETWEEN AUTOPHAGY AND GLYCOLYSIS REGULATES SENESCENCE AND STEMNESS IN HETEROGENEOUS GLIOBLASTOMA TUMOR SUBPOPULATIONS.  25:ii33-ii33. 2023
• P06.15.B IMMUNOTHERAPEUTIC TARGETING OF FIBROBLAST ACTIVATION PROTEIN (FAP) IN TREATMENT REFRACTORY GLIOBLASTOMA USING NOVEL CAR-T CELL THERAPY.  25:ii49-ii49. 2023
• P10.22.B COMBINATION OF ARTS MIMETICS WITH AUTOPHAGY INHIBITORS AS A NOVEL THERAPEUTIC STRATEGY TO OVERCOME APOPTOSIS RESISTANCE IN GLIOBLASTOMA.  25:ii67-ii67. 2023
• PL02.1.A DELINEATING AND TARGETING A NOVEL METABOLISM-BASED POST-TRANSLATIONAL MECHANISM REGULATING THE ABUNDANCE OF THE ‘UNDRUGGABLE’ ONCOPROTEIN C-MYC IN MEDULLOBLASTOMA.  25:ii1-ii2. 2023
• Association of circulating markers with cognitive decline after radiation therapy for brain metastasis.  25:1123-1131. 2023
• Corrigendum to: Association of circulating markers with cognitive decline after radiation therapy for brain metastasis.  25:1010-1010. 2023
• Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539.  25:137-145. 2023
• DDDR-03. DEVELOPMENT OF NOVEL ANTI-BRAIN METASTASIS INHIBITORS.  24:vii98-vii99. 2022
• EPCO-07. NON-GENOMIC DETERMINANTS OF TUMOR CELL PHENOTYPES IN ADULT GLIOBLASTOMA.  24:vii117-vii117. 2022
• EXTH-81. ITGA5 IS A NOVEL IMMUNOTHERAPEUTIC TARGET AGAINST TREATMENT REFRACTORY MEDULLOBLASTOMA.  24:vii228-vii228. 2022
• MODL-05. DISCOVERY OF DYNAMIC MINIMAL RESIDUAL DISEASE STATES IN ADULT GLIOBLASTOMA USING SINGLE CELL TECHNOLOGY.  24:vii291-vii292. 2022
• Clinical management of desmoplastic myxoid tumor, SMARCB1-mutant.  24:847-848. 2022
• Low and steady wins the race: For melanoma brain metastases, is prevention better than a cure?.  24:226-228. 2022
• EXTH-53. ANTI-ROBO1 CAR T CELLS EFFECTIVELY TARGET MALIGNANT BRAIN CANCER.  23:vi175-vi175. 2021
• STEM-02. THERAPEUTIC INTERVENTION OF LUNG-, BREAST-, AND MELANOMA-BRAIN METASTASIS.  23:vi21-vi21. 2021
• STEM-05. FUNCTIONAL MAPPING REVEALS WIDESPREAD REMODELLING AND UNRECOGNIZED PATHWAY DEPENDENCIES IN RECURRENT GLIOBLASTOMA.  23:vi22-vi22. 2021
• TMOD-01. AN IN VIVO FUNCTIONAL GENOMICS SCREEN TO IDENTIFY NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS.  23:vi215-vi215. 2021
• TMOD-15. CHARACTERIZATION OF THE MINIMAL RESIDUAL DISEASE STATE REVEALS DISTINCT EVOLUTIONARY TRAJECTORIES OF HUMAN GLIOBLASTOMA.  23:vi218-vi218. 2021
• STEM-02. THERAPEUTIC INTERVENTION OF LUNG-, BREAST-, AND MELANOMA-BRAIN METASTASIS.  23:vi21-vi21. 2021
• STEM-05. FUNCTIONAL MAPPING REVEALS WIDESPREAD REMODELLING AND UNRECOGNIZED PATHWAY DEPENDENCIES IN RECURRENT GLIOBLASTOMA.  23:vi22-vi22. 2021
• TMOD-01. AN IN VIVO FUNCTIONAL GENOMICS SCREEN TO IDENTIFY NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS.  23:vi215-vi215. 2021
• TMOD-15. CHARACTERIZATION OF THE MINIMAL RESIDUAL DISEASE STATE REVEALS DISTINCT EVOLUTIONARY TRAJECTORIES OF HUMAN GLIOBLASTOMA.  23:vi218-vi218. 2021
• EMBR-22. RATIONAL DEVELOPMENT OF SYNERGISTIC THERAPIES ALONGSIDE BMI1 INHIBITION FOR GROUP 3 MEDULLOBLASTOMA.  23:i10-i10. 2021
• EPCT-11. RURALITY INDEX SCORE AND PEDIATRIC NEURO-ONCOLOGICAL OUTCOME IN ONTARIO.  23:i49-i49. 2021
• EPCT-11. RURALITY INDEX SCORE AND PEDIATRIC NEURO-ONCOLOGICAL OUTCOME IN ONTARIO.  23:i49-i49. 2021
• EPCT-12. NATIONAL MULTICENTERED RETROSPECTIVE REVIEW OF DEMOGRAPHIC, TUMOUR AND INTRAOPERATIVE FEATURES ASSOCIATED WITH THE DEVELOPMENT OF CEREBELLAR MUTISM AFTER PEDIATRIC POSTERIOR FOSSA TUMOUR RESECTION.  23:i49-i49. 2021
• The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis..  23:894-904. 2021
• MBRS-01. DISSECTING REGULATORS OF THE ABERRANT POST-TRANSCRIPTIONAL LANDSCAPE IN MYC-AMPLIFIED GROUP 3 MEDULLOBLASTOMA.  22:iii399-iii399. 2020
• MBRS-01. DISSECTING REGULATORS OF THE ABERRANT POST-TRANSCRIPTIONAL LANDSCAPE IN MYC-AMPLIFIED GROUP 3 MEDULLOBLASTOMA.  22:iii399-iii399. 2020
• CTNI-01. EFFECT OF STEREOTACTIC RADIOSURGERY COMPARED TO WHOLE-BRAIN RADIOTHERAPY FOR LIMITED BRAIN METASTASIS ON LONG TERM COGNITION AND QUALITY OF LIFE: A POOLED ANALYSIS OF RANDOMIZED CLINICAL TRIALS.  22:ii40-ii41. 2020
• CTNI-57. LOW-RISK MENINGIOMA: OUTCOMES FROM NRG ONCOLOGY/RTOG 0539.  22:ii55-ii56. 2020
• STEM-01. TARGETING BRAIN METASTASIS-INITIATING CELLS: A PREVENTATIVE APPROACH.  22:ii196-ii196. 2020
• SURG-05. IDEAL TREATMENT REGIMEN FOR PATIENTS WITH ≥1 BRAIN METASTASIS FROM PRIMARY NON-SMALL-CELL LUNG CANCER – A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS.  22:ii204-ii204. 2020
• TAMI-03. IDENTIFICATION OF NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS THROUGH IN VIVO FUNCTIONAL GENOMICS.  22:ii213-ii213. 2020
• CTNI-01. EFFECT OF STEREOTACTIC RADIOSURGERY COMPARED TO WHOLE-BRAIN RADIOTHERAPY FOR LIMITED BRAIN METASTASIS ON LONG TERM COGNITION AND QUALITY OF LIFE: A POOLED ANALYSIS OF RANDOMIZED CLINICAL TRIALS.  22:ii40-ii41. 2020
• CTNI-57. LOW-RISK MENINGIOMA: OUTCOMES FROM NRG ONCOLOGY/RTOG 0539.  22:ii55-ii56. 2020
• STEM-01. TARGETING BRAIN METASTASIS-INITIATING CELLS: A PREVENTATIVE APPROACH.  22:ii196-ii196. 2020
• TAMI-03. IDENTIFICATION OF NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS THROUGH IN VIVO FUNCTIONAL GENOMICS.  22:ii213-ii213. 2020
• ACTR-13. FINAL RESULTS WITH CHEMORADIOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIAL TUMORS FROM NRG ONCOLOGY/RTOG 9402.  21:vi15-vi15. 2019
• STEM-27. LEVERAGING FUNCTIONAL GENETIC DEPENDENCIES IN TREATMENT-REFRACTORY GLIOBLASTOMA.  21:vi239-vi239. 2019
• ACTR-13. FINAL RESULTS WITH CHEMORADIOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIAL TUMORS FROM NRG ONCOLOGY/RTOG 9402.  21:vi15-vi15. 2019
• STEM-27. LEVERAGING FUNCTIONAL GENETIC DEPENDENCIES IN TREATMENT-REFRACTORY GLIOBLASTOMA.  21:vi239-vi239. 2019
• Updates in the management of intradural spinal cord tumors: a radiation oncology focus.  21:707-718. 2019
• MEDU-25. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICs CONTRIBUTE TO THERAPY EVASION AND RELAPSE.  21:ii108-ii108. 2019
• MEDU-44. MUSASHI-1 IS A MASTER REGULATOR OF ABERRANT TRANSLATION IN GROUP 3 MEDULLOBLASTOMA.  21:ii112-ii113. 2019
• THER-14. SMALL MOLECULE INHIBITOR TARGETING SELF-RENEWAL AS A THERAPEUTIC OPTION FOR RECURRENT MEDULLOBLASTOMA.  21:ii117-ii117. 2019
• MEDU-10. THERAPEUTIC TARGETING OF STEM CELL SELF-RENEWAL IN CHILDHOOD MEDULLOBLASTOMA: STRATEGIES FOR BLOCKING RECURRENCE.  21:ii105-ii105. 2019
• MEDU-25. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICs CONTRIBUTE TO THERAPY EVASION AND RELAPSE.  21:ii108-ii108. 2019
• MEDU-44. MUSASHI-1 IS A MASTER REGULATOR OF ABERRANT TRANSLATION IN GROUP 3 MEDULLOBLASTOMA.  21:ii112-ii113. 2019
• THER-14. SMALL MOLECULE INHIBITOR TARGETING SELF-RENEWAL AS A THERAPEUTIC OPTION FOR RECURRENT MEDULLOBLASTOMA.  21:ii117-ii117. 2019
• GENE-21. A COMMON FETAL DEVELOPMENTAL ORIGIN FOR PFA EPENDYMOMA, PFB EPENDYMOMA, AND CEREBELLAR PILOCYTIC ASTROCYTOMAS?.  20:vi107-vi107. 2018
• PDTM-21. MATCHING OF SINGLE CELL TRANSCRIPTOMICS FROM CEREBELLAR DEVELOPMENT IDENTIFIES PUTATIVE SUBGROUP SPECIFIC CELLS OF ORIGIN FOR MEDULLOBLASTOMA.  20:vi208-vi208. 2018
• RBTT-04. DOES EXERCISE IMPROVE PROGRESSION FREE SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH GLIOBLASTOMA? A TRIAL IN PROGRESS.  20:vi234-vi235. 2018
• TMOD-23. DYNAMIC PATTERNS OF GLIOBLASTOMA CLONAL EVOLUTION IN RESPONSE TO CHEMORADIOTHERAPY.  20:vi273-vi273. 2018
• GENE-21. A COMMON FETAL DEVELOPMENTAL ORIGIN FOR PFA EPENDYMOMA, PFB EPENDYMOMA, AND CEREBELLAR PILOCYTIC ASTROCYTOMAS?.  20:vi107-vi107. 2018
• PDTM-21. MATCHING OF SINGLE CELL TRANSCRIPTOMICS FROM CEREBELLAR DEVELOPMENT IDENTIFIES PUTATIVE SUBGROUP SPECIFIC CELLS OF ORIGIN FOR MEDULLOBLASTOMA.  20:vi208-vi208. 2018
• RBTT-04. DOES EXERCISE IMPROVE PROGRESSION FREE SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH GLIOBLASTOMA? A TRIAL IN PROGRESS.  20:vi234-vi235. 2018
• TMOD-23. DYNAMIC PATTERNS OF GLIOBLASTOMA CLONAL EVOLUTION IN RESPONSE TO CHEMORADIOTHERAPY.  20:vi273-vi273. 2018
• MBCL-09. SALVAGE THERAPY FOR CHILDHOOD MEDULLOBLASTOMA: A SINGLE CENTER EXPERIENCE.  20:i119-i119. 2018
• MBRS-24. INVESTIGATING THE ROLE OF THE RNA BINDING PROTEIN, MUSASHI 1 IN PEDIATRIC GROUP 3 MEDULLOBLASTOMA.  20:i133-i133. 2018
• MBCL-09. SALVAGE THERAPY FOR CHILDHOOD MEDULLOBLASTOMA: A SINGLE CENTER EXPERIENCE.  20:i119-i119. 2018
• MBRS-24. INVESTIGATING THE ROLE OF THE RNA BINDING PROTEIN, MUSASHI 1 IN PEDIATRIC GROUP 3 MEDULLOBLASTOMA.  20:i133-i133. 2018
• CMET-35. PRELIMINARY SCREENING OF A NOVEL EpCAM BISPECIFIC T-CELL ENGAGER (BiTE) ANTIBODY TO TARGET A BMIC POPULATION IN HUMAN BRAIN METASTASES.  19:vi46-vi46. 2017
• CMET-47. PRECLINICAL VALIDATION OF NOVEL THERAPEUTICS TARGETING A BMIC POPULATION IN HUMAN BRAIN METASTASES.  19:vi49-vi49. 2017
• CMET-48. CE7 CANADIAN CLINICAL TRIALS GROUP / ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY. A PHASE III TRIAL OF STEREOTACTIC RADIOSURGERY COMPARED WITH WHOLE BRAIN RADIOTHERAPY (WBRT) FOR 5–15 BRAIN METASTASES.  19:vi49-vi49. 2017
• CSIG-22. A CD133-Akt-Wnt SIGNALING AXIS PROVIDES FUNCTIONAL INSIGHT INTO THE ROLE OF CD133 IN GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS.  19:vi54-vi54. 2017
• EPID-17. A SINGLE CENTER RESTROSPECTIVE REVIEW OF RECURRENT OR TREATMENT REFRACTORY PEDIATRIC MEDULLOBLASTOMA.  19:vi72-vi72. 2017
• IMMU-03. THERAPEUTIC TARGETING OF TUMORIGENIC
EphA2+/EphA3+ BRAIN TUMOR INITIATING CELLS WITH BISPECIFIC ANTIBODY IN HUMAN GLIOBLASTOMA.  19:vi113-vi113. 2017
• NCOG-02. PRETREATMENT VOLUME OF MRI-DETERMINED WHITE MATTER INJURY (WMI) PREDICTS COGNITIVE DECLINE AFTER HIPPOCAMPAL AVOIDANT (HA) WBRT FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGY RTOG 0933.  19:vi137-vi138. 2017
• NCOG-05. TIME TO FUNCTIONAL AND COGNITIVE DECLINE IN A PHASE 3 TRIAL OF TUMOR TREATING FIELDS WITH TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA.  19:vi138-vi138. 2017
• NCOG-06. N107C/CEC.3 (ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY/CANADIAN CANCER TRIALS GROUP): PHASE III TRIAL OF POST-OPERATIVE RADIOSURGERY COMPARED WITH WHOLE BRAIN RADIOTHERAPY FOR RESECTED METASTATIC BRAIN DISEASE: COGNITIVE FUNCTION OF LONG-TERM SURVIVORS.  19:vi138-vi138. 2017
• STEM-17. CHARACTERIZATION OF THE CELL SURFACE PROTEOME IN RECURRENT GLIOBLASTOMA INITIATING CELLS.  19:vi229-vi229. 2017
• STEM-21. CONTEXT-SPECIFIC TUMOR SUPPRESSIVE FUNCTION OF THE CANONICAL Wnt PATHWAY IN PEDIATRIC MEDULLOBLASTOMA HIGHLIGHTS A THERAPEUTIC STRATEGY FOR TREATMENT-REFRACTORY SUBGROUPS.  19:vi230-vi230. 2017
• STEM-42. GENOME-WIDE CRISPR SCREENS IN BRAIN TUMOR INITIATING CELLS (BTICS) IDENTIFY POTENT SENSITIZERS OF CONVENTIONAL CHEMORADIOTHERAPY.  19:vi234-vi235. 2017
• TMOD-02. IDENTIFICATION OF NOVEL MARKERS OF TREATMENT-REFRACTORY RECURRENT GLIOBLASTOMA.  19:vi254-vi254. 2017
• TMOD-03. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE.  19:vi255-vi255. 2017
• TMOD-06. CLONAL DYNAMICS OF HUMAN GLIOBLASTOMA IN RESPONSE TO CHEMORADIOTHERAPY.  19:vi255-vi255. 2017
• CMET-35. PRELIMINARY SCREENING OF A NOVEL EpCAM BISPECIFIC T-CELL ENGAGER (BiTE) ANTIBODY TO TARGET A BMIC POPULATION IN HUMAN BRAIN METASTASES.  19:vi46-vi46. 2017
• CMET-47. PRECLINICAL VALIDATION OF NOVEL THERAPEUTICS TARGETING A BMIC POPULATION IN HUMAN BRAIN METASTASES.  19:vi49-vi49. 2017
• CSIG-22. A CD133-Akt-Wnt SIGNALING AXIS PROVIDES FUNCTIONAL INSIGHT INTO THE ROLE OF CD133 IN GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS.  19:vi54-vi54. 2017
• EPID-17. A SINGLE CENTER RESTROSPECTIVE REVIEW OF RECURRENT OR TREATMENT REFRACTORY PEDIATRIC MEDULLOBLASTOMA.  19:vi72-vi72. 2017
• IMMU-03. THERAPEUTIC TARGETING OF TUMORIGENIC
EphA2+/EphA3+ BRAIN TUMOR INITIATING CELLS WITH BISPECIFIC ANTIBODY IN HUMAN GLIOBLASTOMA.  19:vi113-vi113. 2017
• NCOG-02. PRETREATMENT VOLUME OF MRI-DETERMINED WHITE MATTER INJURY (WMI) PREDICTS COGNITIVE DECLINE AFTER HIPPOCAMPAL AVOIDANT (HA) WBRT FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGY RTOG 0933.  19:vi137-vi138. 2017
• NCOG-06. N107C/CEC.3 (ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY/CANADIAN CANCER TRIALS GROUP): PHASE III TRIAL OF POST-OPERATIVE RADIOSURGERY COMPARED WITH WHOLE BRAIN RADIOTHERAPY FOR RESECTED METASTATIC BRAIN DISEASE: COGNITIVE FUNCTION OF LONG-TERM SURVIVORS.  19:vi138-vi138. 2017
• STEM-17. CHARACTERIZATION OF THE CELL SURFACE PROTEOME IN RECURRENT GLIOBLASTOMA INITIATING CELLS.  19:vi229-vi229. 2017
• STEM-21. CONTEXT-SPECIFIC TUMOR SUPPRESSIVE FUNCTION OF THE CANONICAL Wnt PATHWAY IN PEDIATRIC MEDULLOBLASTOMA HIGHLIGHTS A THERAPEUTIC STRATEGY FOR TREATMENT-REFRACTORY SUBGROUPS.  19:vi230-vi230. 2017
• STEM-42. GENOME-WIDE CRISPR SCREENS IN BRAIN TUMOR INITIATING CELLS (BTICS) IDENTIFY POTENT SENSITIZERS OF CONVENTIONAL CHEMORADIOTHERAPY.  19:vi234-vi235. 2017
• TMOD-02. IDENTIFICATION OF NOVEL MARKERS OF TREATMENT-REFRACTORY RECURRENT GLIOBLASTOMA.  19:vi254-vi254. 2017
• TMOD-03. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE.  19:vi255-vi255. 2017
• TMOD-06. CLONAL DYNAMICS OF HUMAN GLIOBLASTOMA IN RESPONSE TO CHEMORADIOTHERAPY.  19:vi255-vi255. 2017
• MEDU-30. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE.  19:iv44-iv44. 2017
• TRTH-13. BMI1 IS A THERAPEUTIC TARGET IN RECURRENT MEDULLOBLASTOMA.  19:iv54-iv54. 2017
• TRTH-29. CONTEXT-SPECIFIC TUMOR SUPPRESSIVE FUNCTION OF THE CANONICAL WNT PATHWAY IN PEDIATRIC MEDULLOBLASTOMA HIGHLIGHTS A THERAPEUTIC STRATEGY FOR TREATMENT-REFRACTORY SUBGROUPS.  19:iv58-iv58. 2017
• MEDU-30. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE.  19:iv44-iv44. 2017
• TRTH-13. BMI1 IS A THERAPEUTIC TARGET IN RECURRENT MEDULLOBLASTOMA.  19:iv54-iv54. 2017
• TRTH-29. CONTEXT-SPECIFIC TUMOR SUPPRESSIVE FUNCTION OF THE CANONICAL WNT PATHWAY IN PEDIATRIC MEDULLOBLASTOMA HIGHLIGHTS A THERAPEUTIC STRATEGY FOR TREATMENT-REFRACTORY SUBGROUPS.  19:iv58-iv58. 2017
• OS07.2 Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the ARTE trial.  19:iii13-iii13. 2017
• Exercise training for neural recovery in a restricted sample of pediatric brain tumor survivors: a controlled clinical trial with crossover of training versus no training.  19:now177-now177. 2017
• ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA.  18:vi17-vi18. 2016
• IMST-53. THE EFFICACY OF CD133 BiTEs AND CAR-T CELLS IN PRECLINICAL MODEL OF RECURRENT GLIOBLASTOMA.  18:vi98-vi98. 2016
• TMOD-02. Developing models of therapy resistance for the identification of treatment-refractory cell population(s) in human glioblastoma.  18:vi207-vi207. 2016
• TMOD-23. DEVELOPMENT AND APPLICATION OF A NOVEL MODEL OF HUMAN LUNG-TO- BRAIN METASTASIS TO IDENTIFY GENETIC REGULATORS OF BRAIN METASTASIS INITIATING CELLS.  18:vi211-vi212. 2016
• TMOD-37. CHARACTERIZATION OF A UNIQUE BMIC POPULATION IN HUMAN BRAIN METASTASES.  18:vi214-vi215. 2016
• AT-03ATYPICAL TERATOID RHABDOID TUMORS IN THE FIRST YEAR OF LIFE: SHOULD WE TREAT?.  18:iii1.2-iii1. 2016
• CMS-02MRI AND SURGICAL PARAMETERS TO DETERMINE THE RISK OF A CEREBELLAR MUTISM.  18:iii16.2-iii16. 2016
• EPI-04DOES DIAGNOSTIC DELAY AFFECT MORBIDITY IN CHILDREN DIAGNOSED WITH BRAIN TUMOURS?.  18:iii40.3-iii40. 2016
• MB-22ACTIVATED Wnt SIGNALING FOR THE THERAPEUTIC TARGETING OF TREATMENT-REFRACTORY MEDULLOBLASTOMA STEM CELLS.  18:iii101.3-iii101. 2016
• QOS-06REPAIRING THE BRAIN WITH PHYSICAL EXERCISE: AN EXERCISE TRIAL IN PEDIATRIC BRAIN TUMOR SURVIVORS. INSIGHTS FROM CORTICAL THICKNESS ANALYSIS AND DEFORMATION BASED MORPHOMETRY.  18:iii146.2-iii146. 2016
• QOS-21A MODEL OF CARE FOR PEDIATRIC CNS TUMOR PATIENTS.  18:iii149.4-iii149. 2016
• QOS-22IS A SEPARATE AFTERCARE CLINIC FOR PEDIATRIC CNS TUMOR PATIENTS NECESSARY?.  18:iii150.1-iii150. 2016
• QOS-41NEURAL NETWORK DISTURBANCES IN CHILDREN TREATED FOR BRAIN TUMOURS.  18:iii154.2-iii154. 2016
• CMS-02MRI AND SURGICAL PARAMETERS TO DETERMINE THE RISK OF A CEREBELLAR MUTISM.  18:iii16-iii16. 2016
• Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors.  18:350-360. 2016
• ATNT-12PHASE I, TWO-STAGE, OPEN-LABEL, DOSE-ESCALATION STUDY OF BUPARLISIB (BKM120) IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE (TMZ) AND WITH CONCOMITANT RADIATION THERAPY (RT) AND TMZ IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM).  17:v12-v13. 2015
• ATPS-92Bmi1 IDENTIFIES TREATMENT-REFRACTORY STEM CELLS IN HUMAN GLIOBLASTOMA.  17:v38.4-v39. 2015
• ATPS-92Bmi1 IDENTIFIES TREATMENT-REFRACTORY STEM CELLS IN HUMAN GLIOBLASTOMA.  17:v38-v39. 2015
• BMET-31DEVELOPMENT AND APPLICATION OF A NOVEL MODEL OF HUMAN LUNG-TO-BRAIN METASTASIS TO IDENTIFY UNIQUE METASTATIC GENE SIGNATURES.  17:v51.5-v52. 2015
• BMET-31DEVELOPMENT AND APPLICATION OF A NOVEL MODEL OF HUMAN LUNG-TO-BRAIN METASTASIS TO IDENTIFY UNIQUE METASTATIC GENE SIGNATURES.  17:v51-v52. 2015
• NIMG-27USING MR PERFUSION TO STRATIFY PATIENTS WITH TREATED HIGH-GRADE GLIOMAS: DOES IT CORRELATE WITH OVERALL SURVIVAL?.  17:v159.3-v159. 2015
• NIMG-27USING MR PERFUSION TO STRATIFY PATIENTS WITH TREATED HIGH-GRADE GLIOMAS: DOES IT CORRELATE WITH OVERALL SURVIVAL?.  17:v159-v159. 2015
• Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.  17:1504-1513. 2015
• STEM-23PYRVINIUM TARGETS CD133 IN HUMAN GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS.  17:v213.1-v213. 2015
• Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis.  17:868-881. 2015
• MB-14 * DISCOVERING THE TREATMENT REFRACTORY BTIC POPULATION IN GROUP 3 MEDULLOBLASTOMA.  17:iii22-iii22. 2015
• MB-15 * ACTIVATED Wnt SIGNALING TARGETS Sox2+ TREATMENT-REFRACTORY Shh-DEPENDENT MEDULLOBLASTOMA STEM CELLS.  17:iii23-iii23. 2015
• MB-15ACTIVATED Wnt SIGNALING TARGETS Sox2+ TREATMENT-REFRACTORY Shh-DEPENDENT MEDULLOBLASTOMA STEM CELLS.  17:iii23-iii23. 2015
• Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.  17:430-439. 2015
• RM-06IN VITRO CLONAL EVOLUTION OF GLIOBLASTOMA (GBM) BRAIN TUMOUR INITIATING CELLS (BTIC) TO MODEL TUMOUR RECURRENCE.  16:v187-v187. 2014
• SC-33POLYCOMB GROUP PROTEIN Bmi1 CONTROLS NEURAL STEM AND PROGENITOR CELL MAINTENANCE AND GLIOBLASTOMA TUMOUR DEVELOPMENT.  16:v204-v204. 2014
• P17.73 * IN VITRO ANALYSIS OF CYTOTOXIC EFFECTS OF BRIVARACETAM AND LACOSAMIDE ON HUMAN GLIOBLASTOMA CELLS.  16:ii104-ii104. 2014
• MEDULLOBLASTOMA.  16:i71-i96. 2014
• The combined use of surgery and radiotherapy to treat patients with epidural cord compression due to metastatic disease: a cost-utility analysis..  14:631-640. 2012
• Abstracts from the 2011 BNOS Conference, June 29 – July 1, 2011, Homerton College, Cambridge.  13:ii1-ii14. 2011
• Diffusion tensor imaging of white matter after cranial radiation in children for medulloblastoma: Correlation with IQ.  8:244-252. 2006

has subject area

• 1109 Neurosciences (FoR)
• 1112 Oncology and Carcinogenesis (FoR)
• Oncology & Carcinogenesis (Science Metrix)

Identity

International Standard Serial Number (ISSN)

• 1522-8517

Electronic International Standard Serial Number (EISSN)

• 1523-5866